文章预览
SCI 23 October 2024 Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (The New England Journal of Medicine, IF: 96.2) Y. Cheng, D.R. Spigel, B.C. Cho, K.K. Laktionov, J. Fang, Y. Chen, Y. Zenke, K.H. Lee, Q. Wang, A. Navarro, R. Bernabe, E.L. Buchmeier, J.W.-C. Chang, Y. Shiraishi, S.S. Goksu, A. Badzio, A. Shi, D.B. Daniel, N.T.T. Hoa, M. Zemanova, H. Mann, H. Gowda, H. Jiang, and S. Senan, for the ADRIATIC Investigators CORRESPONDENCE TO: s.senan@amsterdamumc.nl BACKGROUND 背景 Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy. 在标准治疗基于铂的同步放化疗后没有疾病进展的局限期小细胞肺癌患者中，使用度伐利尤单抗合并使用或不使用tremlimumab的辅助治疗可能具有疗效。 METHODS 方法 In a phase 3, double-blind, randomized, p
………………………………
